Gapping up
In reaction to disappointing earnings/guidance:
- IVC +20.9%, CYBR +14.6%, SNBR +14.3%, MFGP +13.6%, YETI +10.7%, BLMN +6.6%, AZN +6.1%, PDS +6.1%, VNDA +5.1%, CSCO +4.5%, STNG +4.3%, GLOG +3.7%, AR +3.6%, CTRE +3.5%, TRTN +3.5%, GOOS +3.2%, DIOD +2.9%, ZBRA +2.7%, YELP +2.1%, ETRN +2.1%, BAM +2.1%, MRO +1.7%, IRM +1.7%, TU +1.7%, ZTS +1.5%, CCEP +1.4%, WM +1.4%, SBGL +1.2%, EQIX +1.1%, .
Other news:
- SOLO +28.4% (continued momentum after hosted virtual roadshow webinar yesterday)
- DBVT +12.3% (announces that its planned resubmission of the Biologics License Application to the FDA for Viaskin Peanut in the treatment of peanut-allergic children 4 to 11 years of age is anticipated in Q3)
- MDGS +9.6% (considering expanding portfolio of activities to include ventures in the field of CBD and medical cannabis in territories outside the US)
- CVRS +7.9% (seeks pre-market clearance from the FDA to use the CorPath GRX System in neurovascular intervention)
- GNC +6.5% (announces that Harbin Pharmaceutical has completed the final $150 mln investment of its previously announced $300 mln strategic investment)
- MDR +2.6% (modestly rebounding from yesterday's 27% decline), .
Analyst comments:
- CDXC +5.8% (initiated with a Buy at B. Riley FBR; tgt $7)
- ELVT +4.3% (upgraded to Buy with $6 tgt at BTIG)
- SYF +1.4% (upgraded to Buy from Neutral at Goldman)
- XOM +1.3% (upgraded to Outperform from Underperform at Macquarie)
- TEVA +1.1% (upgraded to Outperform from Mkt Perform at Raymond James)
